Vitro Biopharma

Biotechnology company focused on developing Wharton's jelly-derived cell therapies for autoimmune diseases and inflammatory disorders

Vitro Biopharma is an innovative biotechnology company focused on developing Wharton's jelly-derived cell therapies for autoimmune diseases and inflammatory disorders. Our goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market.

Company Pipeline

The pipeline of Vitro Biopharma includes five core development programs. We intend to initiate our FDA cleared clinical trials for Long COVID and PTHS in 2023 pending receipt of sufficient funding. In addition, we are also currently focused on our pre-clinical development programs for multiple sclerosis (“MS”) and Lupus/systemic lupus erythematosus (“SLE”). We plan to submit two additional IND applications to the FDA to initiate Phase 1/2a clinical trials to assess the safety and efficacy of AlloRx Stem Cell therapy in adults with Lupus (SLE) in 2023 and in adults with MS in late 2023 or 2024, which will be subject to FDA clearance prior to the initiation of any clinical trials for these indications.

The development programs are illustrated in the pipeline chart below, including the Phase 1/2a clinical trials for PTHS and Long COVID (PASC):